Filing Flows › Sonoma Pharmaceuticals (SNOA) › Q4 FY26
Sonoma Pharmaceuticals (SNOA) Q4 FY26 earnings results (fourth quarter fiscal 2026)
10-K filed Jun 16, 2026
Sonoma Pharmaceuticals (SNOA) reported revenue of $5.6M for the fourth quarter fiscal 2026 (Q4 FY26), +48% from a year earlier and +28% from the quarter before. Operating margin was -6.3%, net loss $581K (10.4% of revenue).
Sonoma Pharmaceuticals, Q4 FY26: revenue $5.6M (+48% year over year), operating margin -6.3%, net loss $581K, operating cash flow −$519K. The chart follows the revenue to costs, profit and cash.
| Q4 FY26 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $5.6M | +28% | +48% |
| Operating profit | −$351K | — | — |
| Net earnings | −$581K | — | — |
| Operating cash flow | −$519K | — | — |
What changed
Revenue was $5.6M in Q4 FY26, up 48% year over year and up 28% from the previous quarter.
Gross margin was 39.2%, down 1.5 points from Q4 FY25. Operating costs exceeded revenue by $351K, an operating margin of -6.3%. Operating expenses grew 16% against revenue growth of 48%. The fastest-growing cost line was Research & development (+33%). The quarter ended with a net loss of $581K, narrower than the previous quarter's $819K loss.
Operating cash flow was −$519K. Non-cash charges added back $33K of depreciation and amortization and $135K of share-based compensation. Working capital and other items used $106K. Capital expenditures of $29K exceeded it, leaving free cash flow of −$548K.
Questions
What was Sonoma Pharmaceuticals' revenue in the fourth quarter fiscal 2026?
Sonoma Pharmaceuticals (SNOA) reported revenue of $5.6M for the fourth quarter fiscal 2026 (Q4 FY26), +48% from a year earlier and +28% from the quarter before.
Was Sonoma Pharmaceuticals profitable in the fourth quarter fiscal 2026?
Operating loss was $351K (-6.3% of revenue) and net loss $581K.